



www.iaterion.com

IATERION, INC.

CORPORATE OVERVIEW

MARCH, 2021

IATERION, INC.

- OVERVIEW
- DRUG DEVELOPMENT PLATFORMS/ TECHNOLOGIES
- PIPELINE
- PERSONNEL

CORPORATE PHILOSOPHY


- Through transformative science and detailed attention to complexity, we're creating the next generation of life-supporting medicines
- Careful molecular toxicology is pursued prior to advancing any lead compound, to create safe therapies
- We are translating nature into new treatments.



ANTIVIRAL DRUGS

- We identified multiple antiviral compounds with multiple novel mechanisms of action inhibiting viral entry, replication and release
- Our antiviral drugs are utilizing cross kingdom compounds
- We tested plant derived small molecule chemicals, the phytoanticipins and the phytoalexins, which are at the forefront of plant antiviral defense

Given the massive number of coronaviruses carried by different bat species, the high plasticity in receptor usage and other features such as adaptive mutation and recombination, frequent interspecies transmission from bats to animals and humans is expected



IMMUNE MODULATING DRUGS

- Our immune modulators are aimed to be used for acute viral infections, where the immune system's reaction is the major cause of disease manifestation, long-term damage and death
- We identified multiple compounds that target the pattern recognition receptors (PRRs) family, which are the first line of defense against microorganisms
- The novelty of the compounds is their activity in the presence of viruses: increasing Type-1 interferon response while not inhibiting T-cell response

Although the cause of death from COVID-19 is the infection by SARS-CoV-2, it is the immune response that is responsible for the symptoms, potential complications and possible death.



NUCLEAR RECEPTORS SELECTIVE MODULATORS

- We developed a diverse platform for nuclear receptors selective modulation including selective agonists, selective receptor modulators, estrogen receptor downregulators, ER α reprogramming ligands and ER β selective ligands
- Estrogen receptors modulation results in an opportunity for many therapies for Women's Health indications including menopausal symptoms, breast cancer, vaginal dryness, osteoporosis, prevention of Type-2 diabetes and metabolic syndrome among others
- Other nuclear receptors include the androgen receptor, glucocorticoid receptor, thyroid receptor, progesterone receptor and the peroxisome proliferator-activated receptors

Approximately 10–20% of current FDA-approved drugs target nuclear receptors. These drugs have a market value of 30 billion dollars per year.



ONCOLOGY

- At laterion we harness multiple different pathways related to cellular mechanisms that cancer cells employ to thrive, while ensuring in advance that their deployment will not damage normal cells
- Our drugs address multiple mechanisms to exert control over cancer cells including BIM inhibitors, dual mTOR inhibitors, glycolysis inhibitors among others
- We also focus on cancer prevention, which deploys mechanisms associated with increased risks that accelerate mutations accumulation and proliferation resulting in cancer

In the U.S., more than 1.8 million new cancer cases are expected to be diagnosed in 2020 and about 606,520 Americans are expected to die of cancer in 2020.



AVIM1

- AVIM1 is designed to harnesses multiple antiviral targets to neutralize the virus, as well as modulate the viral immune response to prevent a cytokine storm
- The immune modulators target the pattern recognition receptors (PRRs), such as the toll-like-receptors (TLRs) in infected cells
- The TLRs initiate the so-called pathogen-associated molecular pattern (P/MAMP)-triggered immune (PTI) response to inhibit immune effector contributing to inflammation and tissue damage

Given the current COVID-19 pandemic, loss of life, mounting mutations and resulting economic recession, the need for a pan-anti-corona virus therapy is urgent.



R_xUMINA

- Breast density has been shown to be strongly associated with breast cancer risk among premenopausal and postmenopausal women.
- Increased mammographic density is associated with larger tumors, positive lymph nodes, more aggressive breast tumors including triple negative tumors
- There are multiple biological mechanisms associated with increased breast density including extracellular matrix, adipose and epithelial tissues cross talk, genetics, hormones, diet and inflammation


R_xumina addresses multiple mechanisms associated with increased breast density as well as breast cancer risk reduction. The combination targets multiple cell types involved with breast tissue remodeling that results in increased breast density and cancer risk.



CC3 & CC6

- Women with tumors resistant to ET have a poor prognosis resulting in critical need for new drugs to treat resistant breast cancer
- CC3 and CC6 are a new class of drugs called Bim down-regulators for endocrine resistant breast tumors
- Bim is upregulated in endocrine resistant breast cancer

Approximately two-thirds of breast cancer tumors are classified as estrogen receptor positive, expressing ER α . While there are treatments to address the estrogenic effect the majority of these women will become resistant to estrogen therapy.



CC7

- Current nuclear receptor ligand drugs interact with their nuclear receptors, they can promote serious adverse effects, in addition to the beneficial effects that the drug is prescribed for
- Our initial drug is designed to capitulate on estrogen's pharmacological ability to treat menopausal symptoms and to reduce type 2 diabetes risk and other long-term conditions associates with postmenopausal women
- laterion Inc. plans to market a new class of drugs that we discovered called nuclear receptor reprogramming (NRRP) drugs

Menopause hormone therapy include risks such as breast cancer, clotting events and early Alzheimer's disease. Since 2002, when these risks were revealed in the Women's Health Initiative (WHI) trials, MHT use has dropped by 80%.



PERSONNEL

- Isaac Cohen, OMD, PhD- Chief Executive Officer
- Dale Leitman, MD, PhD- Chief Scientific Officer
- Klaus Kohl, PhD- Chief Technology Officer
- Carlos Milla, MD- Acting Advisory Chief Medical Officer
- Uwe Christians, MD, PhD- Scientific Advisor for Clinical Pharmacology
- Wally Wang, PhD- Scientific Advisor for Nuclear Receptors
- Chaoshen Yuan, MD, PhD- Senior Scientist
- Mark Rosenthal, MD- Scientific Advisor for Gerontology



CONCLUSION

- laterion developed multiple platforms for drug development utilizing multiple biological mechanisms
- laterion has a robust pipeline of drugs for multiple indications
- laterion developed the opportunity to also develop novel nutritional products from its natural compounds
- laterion's drugs can result in multibillion potential

